Nmda free trial

N-Methyl-D-aspartate antagonists and working memory performance: comparison with the effects of scopolamine, propranolol, diazepam, and phenylisopropyladenosine. Behav Neurosci. Walker DL. Brain Res.

McNamara RK. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev. Kim J. Effects of amygdala, hippocampus, and periaqueductal gray lesions on short- and long-term contextual fear. Thompson DM. Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Phencyclidine in combination with d-amphetamine: differential effects on acquisition and performance of response chains in monkeys.

Buffalo EA. Acute behavioral effects of MK in rhesus monkeys: assessment using an operant test battery. Frederick DL.

Acute behavioral effects of phencyclidine on rhesus monkey performance in an operant test battery. Javitt DC. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. Rosenbaum G. Comparison of Sernyl with other drugs: simulation of schizophrenic performance with Sernyl, LSD, and amobarbital Amytal.

Attention, motor function and proprioception. Arch Gen Psychiatry. Davies BM. The effect of 1-arylcyclohexylamine Sernyl on 12 normal volunteers, J Ment Sci. Bakker CB. Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry. Cohen BD. Comparison of phencyclidine hydrochloride Sernyl with other drugs. Pandit SK. Br J Anaesth. Jansen KLR. Ketamine - can chronic use impair memory? Int J Addictions.

Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Hampton RY. Stereospecific binding of 3H-phencyclidine in brain membranes. Life Sci. Rothman SM. Excitotoxicity and the NMDA receptor. Harris JA. Attention, learning and personality during ketamine emergence: a pilot study. Anesth Analg. Ghoneim MM. Ketamine: behavioral effects of subanesthetic doses.

J Clin Psychopharmacol. Krystal JH. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Malhotra AK. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Harborne GC. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol. Newcomer JW. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment in schizophrenia.

Adler CM. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. NMDA antagonist-induced decrease in working and declarative memory in healthy humans. Soc Neurosci Abstr. Smith EE. Storage and executive processes in the frontal lobes. Vogt BA. Primate cingulate cortex chemoarchitecture and its disruption in Alzheimer's disease.

Handbook of Chemical Neuroanatomy. Vol The Primate Nervous System. Part I. Johnstone M. Sernyl CI in clinical anaesthesia. Luby ED.

Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiatry. Model psychoses and schizophrenia. Corssen G. Dissociative anesthesia: further pharmacological studies and first clinical experience with the phencyclidine derivative CI Domino EF. Abnormal mental states induced by phencyclidine as a model of schizophrenia. Lodge D. Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. Excitatory amino acids and phencyclidine-like drugs.

Excitatory Amino Acid Transmission. New York: Alan R Liss. Kristensen JD. Herrling P. Results from animal models and first results in humans. Grotta J. Safety and tolerability of the glutamate antagonist CGS Selfotel in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Muir KW. Clin Neuropharmacol. Zukin RS. Specific [3H]phencyclidine binding in rat central nervous system.

Vincent JP. Angrist B. The phenomenology of experimentally induced amphetamine psychosis - preliminary observations. Freedman DX. On the use and abuse of LSD. LSD: the bridge from human to animal. In: Jacobs BL, ed. Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives.

New York: Raven Press. Amphetamine psychosis: behavioral and Biochemical aspects. J Psychiatr Res. Janowsky DS. Amphetamine psychosis and psychotic symptoms.

Psychopharmacol Berl. Lieberman JA. Provocative tests with psychostimulant drugs in schizophrenia. Bowers MB. Early neuroleptic response: clinical profiles and plasma catecholamine metabolites.

Gillin JC. The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Yesavage JA. Acute phencyclidine PCP intoxication: psychopathology and prognosis. J Clin Psychiatry. Erard R. The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J Psychedelic Drugs. Ban TA. Observations on the action of Sernyl - a new psychotropic drug.

Can Psychiatr Assoc J. Reich DL. Ketamine: an update on the first 25 years of clinical experience. Can J Anaesth. Marshall BE. General anesthetics.

The Pharmacological Basis of Therapeutics. New York: Pergamon Press. Karp HN. Phencyclidine poisoning in young children. J Pediatr. Welch MJ. PCP intoxication in young children and infants. Clin Pediatr Phila. Baldridge EB. Emerg Med Clin North Am. Tsai G. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.

Ulas J. D'souza DC. Glycine site agonist of the NMDA receptor: a review. CNS Drug Rev. Endogenous excitotoxins and neuropathological disorders. In: Lodge D, ed. Excitatory Amino Acids in Health and Disease. Glutamate receptor dysfunction and schizophrenia. Coyle JY. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry. Glycine agonists: what can they teach us about schizophrenia? Guanabenz effects on NMDA antagonist-induced mental symptoms in humans.

Anand A. Reduction in ketamine effects in humans by lamotrigine. Goff DC. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Heresco-Levy U. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Moghaddam B. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Adams B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. Treatment-emergent AEs were seen in Serious adverse events SAEs have been very uncommon across all memantine studies.

One patient died before randomization, whereas 4 patients died in each randomized treatment arm memantine and placebo. There were 7 deaths, 2 of which occurred in the memantine group.

Most SAEs, including all of the deaths, were considered to be unrelated to study medication. No clinically relevant changes in vital signs, laboratory data, or electrocardiography measurements were reported in any of the studies. The investigators concluded that these SAEs were not related to the study drug van Dyck et al Overall the type and incidence of SAEs were similar between groups.

One participant death occurred in each group during the trial, neither considered treatment-related by the investigators Peskind et al In adult and elderly patients the recommended maintenance dose of memantine is 20 mg daily, administered as 10 mg twice daily Forest Laboratories The recommended starting dose for memantine is 5 mg daily and the dosage titration is by 5 mg daily in weekly increments to 10 mg twice daily by Week 4. However, a new study conducted in patients with moderate to severe AD has shown that once-daily dosing of memantine at 20 mg was as well tolerated as the twice-daily dosing Jones et al Memantine was first developed in Europe in the s, but its action at NMDA receptors was not recognized until the late s Parsons et al It was subsequently registered in Germany in for the treatment of cerebral ischemia and AD.

Since then, based on studies including those detailed in this review Winblad and Poritis ; Reisberg et al ; Tariot et al , it has been approved for use in the United States in patients with moderate to severe AD and in Europe for patients with moderately severe to severe AD.

Moreover, based in part on the study of Peskind et al , applications have been made to the regulatory authorities in Europe and in the United States to expand its use to mild to moderate AD Forest Laboratories ; Lundbeck Pharmaceuticals Although the United States Food and Drug Administration FDA has issued a non-approvable letter for this expanded indication, the matter remains under discussion Forest Laboratories In these severe patients, the use of memantine may therefore become even more important.

Although memantine is approved only for AD, two double-blind studies have suggested possible beneficial effects of memantine in patients with vascular dementia Orgogozo et al ; Wilcock et al A pooled analysis of these studies further suggested that memantine may be more effective in subjects with small-vessel disease white matter lesions and or lacunae Mobius and Stoffler However, a recent review of multinational pharmacoeconomic data concluded that the limited available data suggest the cost-effectiveness of memantine treatment when compared with no treatment in patients with moderate to severe AD Plosker and Lyseng-Williamson This conclusion was further supported by a Swedish study showing that, compared with no treatment, memantine treatment was predicted to be associated with lower costs of care, longer time to dependence and institutionalization, and gains in quality-adjusted life-years Jonsson In conclusion, well-designed studies have demonstrated that memantine is safe and effective in modifying the progression of cognitive, functional and global outcomes in patients with moderate to severe AD, either as monotherapy or in combination with the ChEI donepezil.

Although there is still debate on the efficacy of this medication in the treatment of earlier stages of this disease, emerging data suggest its potential benefits in patients with mild to moderate AD.

Despite recent NICE recommendations indicating that memantine is not cost effective and that it should be prescribed only as part of clinical studies, preliminary pharmacoeconomic data analyses support the use of memantine as a cost-effective treatment in the AD patient population. Drs Tampi and van Dyck receive grant support from Forest Laboratories. National Center for Biotechnology Information , U.

Journal List Neuropsychiatr Dis Treat v. Neuropsychiatr Dis Treat. Author information Copyright and License information Disclaimer. All rights reserved. This article has been cited by other articles in PMC. Mechanisms of action and pharmacokinetics During normal synaptic transmission the NMDA receptor is activated by the binding of glutamate, the major excitatory neurotransmitter in the central nervous system CNS Lipton Memantine for moderate to severe AD Memantine has been evaluated in moderate to severe AD patients in four major studies: 3 involving memantine monotherapy and 1 involving combination therapy with donepezil.

Table 1 Mean change on outcome measures in clinical trials of memantine. Open in a separate window. Table 2 Common rating scales used in dementia studies. Monotherapy studies Winblad and Poritis study This was a week, placebo-controlled trial of memantine 10 mg daily, conducted in nursing home residents and psychiatric hospital patients. Reisberg et al study The first pivotal trial of memantine in the United States was a week, placebo-controlled outpatient trial of memantine 10 mg twice daily.

Combination therapy studies The established efficacy of ChEIs in AD Cummings naturally raised the question of whether memantine would also provide clinical benefit for moderate to severe stage patients already treated with one of these drugs. Tariot et al study This study involved subjects with probable AD who had received stable doses of donepezil for at least 3 months who were randomized to receive memantine 10 mg twice daily or placebo.

Memantine for mild to moderate AD Memantine has been evaluated in mild to moderate AD patients in 3 major studies: 2 involving memantine monotherapy, and 1 involving combination therapy with ChEIs. Monotherapy studies Peskind et al study A study of memantine monotherapy in subjects with mild to moderate AD has recently been reported by Peskind et al Bakchine et al study A second study of memantine monotherapy in mild to moderate AD patients has been conducted in Europe and presented in abstract form Bakchine et al Limitations of memantine studies A potential limitation common to all previous memantine studies contained in this review is the use of LOCF as a means of imputing missing data.

Safety and tolerability In the trials detailed in this review, memantine has shown excellent safety and tolerability, with a frequency of adverse events AEs similar to placebo.

Table 3 Treatment-emergent adverse events in outpatient trials of memantine. Dosing schedule In adult and elderly patients the recommended maintenance dose of memantine is 20 mg daily, administered as 10 mg twice daily Forest Laboratories Memantine in clinical practice Memantine was first developed in Europe in the s, but its action at NMDA receptors was not recognized until the late s Parsons et al Conclusion In conclusion, well-designed studies have demonstrated that memantine is safe and effective in modifying the progression of cognitive, functional and global outcomes in patients with moderate to severe AD, either as monotherapy or in combination with the ChEI donepezil.

Diagnostic and Statistical Manual of Mental Disorders. J Neurosci. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. The Neuropsychiatric Inventory; comprehensive assessment of psychopathology in dementia. Int J Geriatr Psychiatry. CNS Drugs. Behavioral activities in demented geriatric patients. Gerontol Clin. New York: Forest Laboratories, Inc; Memantine combined with an acetylcholinesterase inhibitor - hope for the future.

Neuropsychiatric Disease and Treatment. J Int Neuropsychol Soc. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol. Alzheimer disease in the US population: prevalence estimates using the census.

Arch Neurol. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm Suppl. How can we manage the costs? Am J Geriatric Pharmacother. Eur Arch Psychiatry Clin Neurosci. Neurosci Lett. New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc Dis.

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial MMM Stroke. These MRI findings have both mechanistic and clinical significance. First, the findings suggest that an NMDA receptor antagonist, such as memantine, attenuates the effects of corticosteroids in the same hippocampal subregion in humans as in animals. It is not, however, possible to determine in humans whether the changes are related to reversal of dendritic shortening, changes in overall neuronal size or number, changes in fluid, or other mechanisms.

Memantine administration over a period of 24 weeks appeared to partially reverse some of hippocampal atrophy in this population. In adults, an annual reduction in hippocampal volume of about 0. Thus, 24 weeks of memantine therapy may have reversed, on average, about two years of normal atrophy. At least in healthy controls, the relationship between hippocampal volume and memory is weak [ 32 ].

Our prior research has not found statistically significant relationships between declarative memory performance and hippocampal volume in corticosteroid-treated patients [ 19 , 33 ]. In the present study, the HVLT was used because multiple equivalent versions are available, which was needed for a longitudinal study. Thus, we may have not been able to detect small cognitive changes over a relatively brief period of time with this instrument.

Alternatively, the changes observed in the hippocampal subfield volume may be an earlier and more sensitive biomarker of the ability of memantine to reverse the effects of corticosteroids on the hippocampus compared to memory testing. The study has limitations. While the within-subject crossover design has many advantages in a neuroimaging study and has greater statistical power than an analysis of a parallel-group sample of the same size, carryover effects are possible.

However, the very long four-week washout period was about 10 times the half-life of memantine. While large for a study of this nature, this sample size was not sufficient to detect subtle effects of memantine on memory or the hippocampus. The attrition rate is also a limitation. Therefore, we only had MRI data on 26 participants. Since memantine appeared to be well-tolerated the relatively high attrition rate may reflect the length of the study one year and the medically ill patient population.

Strengths of the study include the double-blind, placebo-controlled design and the state-of-the art hippocampal subfield imaging analysis. To our knowledge, no published research studies have examined hippocampal subfields in corticosteroid-treated patients. The findings translate preclinical research on the ability of NMDA receptor antagonists to block the effects of corticosteroids on the hippocampus and highlight the importance of the NMDA receptor in mediating the effects of corticosteroids on the hippocampus.

Furthermore, the findings suggest memantine may have potential as a neuroprotective agent in people receiving prescription corticosteroids therapy or with elevated levels of endogenous cortisol.

The authors declare no competing interests. Chronic stress alters synaptic terminal structure in hippocampus. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment.

Behavioral and structural adaptations to stress. Front Neuroendocrinol. McEwen BS. Stress-induced remodeling of hippocampal CA3 pyramidal neurons. Brain Res. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews.

Distribution of N-methyl-D-aspartate-sensitive L-[3H]glutamate-binding sites in rat brain. NMDA receptor subunits change after synaptic plasticity induction and learning and memory acquisition. Neural Plast. Article Google Scholar. Glutamate receptor ion channels: structure, regulation, and function.

Pharm Rev. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis. Benarroch EE. NMDA receptors: recent insights and clinical correlations. N-methyl-d-aspartate receptor-mediated calcium overload and endoplasmic reticulum stress are involved in interleukin-1beta-induced neuronal apoptosis in rat hippocampus. J Neuroimmunol. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors.

Behavioral stress modifies hippocampal plasticity through N-methyl-D-aspartate receptor activation. Modification of hippocampal markers of synaptic plasticity by memantine in animal models of acute and repeated restraint stress: implications for memory and behavior. Neuromolecular Med. The effect on memory of chronic prednisone treatment in patients with systemic disease.

Glucocorticoids and hippocampal atrophy after heart transplantation. Ann Thorac Surg. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry. Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy.

A quantitative evaluation of cross-participant registration techniques for MRI studies of the medial temporal lobe. Pattern separation in the hippocampus. Trends Neurosci. Age-related memory deficits linked to circuit-specific disruptions in the hippocampus. A reproducible evaluation of ANTs similarity metric performance in brain image registration.

Multi-atlas segmentation with joint label fusion. Explicit B-spline regularization in diffeomorphic image registration. Front Neuroinform.